Progression due to new metastases | Progression due to pre-existing lesions | No reported disease progression | |||||||
---|---|---|---|---|---|---|---|---|---|
Eribulin | TPC | Total | Eribulin | TPC | Total | Eribulin | TPC | Total | |
(n = 139) | (n = 68) | (N = 207) | (n = 189) | (n = 73) | (N = 262) | (n = 180) | (n = 113) | (N = 293) | |
Median OS, months (95 % CI) | 12.3 (9.9, 13.4) | 8.4 (7.0, 14.4) | 11.1 (8.9, 13.1) | 13.0 (11.1, 14.5) | 11.1 (8.7, 15.3) | 12.2 (11.0, 14.2) | 15.8 (12.1, 19.1) | 10.7 (9.2, 14.8) | 13.0 (11.1, 16.9) |
HR eribulin vs. TPC (95 % CI) | 0.76 (0.51, 1.12) | – | 0.74 (0.50, 1.10) | – | 0.77 (0.54, 1.10) | – | |||
p value | 0.16 | – | 0.14 | – | 0.16 | – |